Hepatitis C News

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study.

Collaborative practice agreements between pharmacists and rural clinics that targeted American Indian/Alaska Native populations led to successful outcomes for patients with hepatitis C virus, according to findings recently published in the Journal of Primary Care and Community Health.

Researchers discovered diverse hepatitis C genotype 4 strains and new genotype 7 strains in sub-Saharan African countries with NS3 and NS5A polymorphisms associated with resistance to direct-acting antivirals in other genotypes, according to recently published data.

Mavyret was safe and efficacious for patients with chronic hepatitis C who underwent liver or kidney transplantation, according to a recently published study.

The safety and efficacy of direct-acting antivirals for hepatitis C have begun to move HCV from the forefront of chronic liver disease into the realm of potential elimination. Many researchers are now focusing on the next task: improved care and possible cure of other viral hepatitis infections.

Results from a national survey showed that hepatitis C prevalence was higher in the West and Appalachian states between 2013 and 2016 compared with other areas, as reported in JAMA Network Open.

Extrahepatic cancer was more common in patients with hepatitis C and was the leading cause of death in patients who achieved sustained virologic response compared with the general population, according to results of a French cohort study.

This year at The Liver Meeting, data presented on hepatitis C treatment highlighted continued significantly positive outcomes from direct-acting antiviral therapy, reduced rates of hepatocellular carcinoma, and improved outreach and screening techniques.

Sovaldi-based therapy was safe and effective in as short as 8 weeks for treating hepatitis C in patients with cancer and may induce remission of non-Hodgkin’s lymphoma, according to a recently published study.